Heart failure research is a most active area of research in academic, industrial and government-sponsored research and receives intense clinical attention. The recent recognition that inflammation is a risk factor and prognostic factor for heart disease has laid ground for preventive medicine and even anti-infective strategies in prevention and treatment of heart failure.

Provides a new perspective on the etiology of cardiac failure Presents latest developments Discusses future treatments for heart failure Of great value to researchers as well as clinicians

Autorentext
Heart failure research is a most active area of research in academic,
industrial and government-sponsored research and receives intense
clinical attention. The recent recognition that inflammation is a risk
factor and prognostic factor for heart disease has laid ground for
preventive medicine and even anti-infective strategies in prevention and
treatment of heart failure.

Inhalt
Inflammation a new frontier in cardiac disease and therapeutics.- Pathological aspects and inflammation biomarkers in cardiac diseases.- A biomarker of inflammation in cardiovascular diseases.- Inflammation and coronary artery disease.- Inflammatory cells and their metalloproteinases in cardiac diseases.- The role of matrix metalloproteinases in LV remodeling following myocardial infarction.- Matrix metalloproteinases in heart failure: evidence from experimental models.- Inflammatory cytokines in cardiac diseases.- The clinical experience with anti-cytokine therapy in heart failure.- The role of IL-6 and related cytokines in myocardial remodeling and inflammation implication for cardiac hypertrophy and heart failure.- Toll-like receptors and the cardiovascular system.- The role of IL-6 in experimental and clinical heart failure.- Oxygen and nitrogen reactive radicals in cardiac inflammation and disease.- Myocardial nitric oxide in cardiac remodeling.- Identification and role of inflammatory oxygen free radicals in cardiac ischemia and reperfusion injury.- The immune and complement system and cardiac diseases.- Immune-mediated myocarditis and interleukin-10.- Immunomodulation in heart failure: experimental models.- The role of complement in myocardial inflammation and reperfusion injury.- Inflammatory signaling pathways in cardiac diseases.- The role of immune and inflammatory cytokines in ischemic preconditioning of the heart identification of novel cardiac cell survival signaling programs.- Stress-activated signals and their role in myocardial ischemia.- p38 MAPK in cardiac remodeling and failure: cytokine signaling and beyond.- Inflammation and myocarditis.- Inflammation and myocarditis.- The inflammatory process in experimental myocarditis.- Nuclearfactors in cardiac disease.- Peroxisome proliferator activated receptors, inflammation, the vasculature and the heart.- Chemokines and cardiac diseases.- Role of chemokines in the pathogenesis of congestive heart failure.- Neurohormonal mediators and cardiac inflammation.- The role of endothelin-1 in myocardial inflammation and fibrosis.- Cyclooxygenases and cardiac diseases.- Cyclo-oxygenase-2 and myocardial ischemia.- Inflammation and arrhythmias.- Inflammation as a cause and consequence of atrial fibrillation.- Summary: Immune and inflammatory modulators as potential therapeutic targets for cardiac diseases.